melanoma-overexpressed antigen 1 (36-44)

Melanoma-overexpressed antigen 1 (36-44) is a synthetic peptide fragment derived from the melanoma-associated MELOE-1 protein, encompassing amino acid residues 36 to 44. As a defined peptide epitope, it holds significant value in immunological and cancer research, particularly in the context of antigen presentation, T-cell recognition, and tumor immunology. The sequence is recognized for its relevance in studies of tumor antigenicity, immune surveillance, and the development of targeted immunotherapies. Its well-characterized structure and immunogenic potential make it a critical reagent for experimental systems exploring melanoma antigens and peptide-based immune responses.

Epitope mapping: Researchers frequently employ this peptide as a model antigen for the precise mapping of T-cell epitopes within the MELOE-1 protein. By integrating it into in vitro assays or ex vivo cell culture experiments, investigators can identify and characterize CD8+ T-cell responses specific to this epitope. Such studies are instrumental in delineating the fine specificity of immune recognition, facilitating the identification of immunodominant regions relevant to melanoma immunology.

Antigen presentation studies: The peptide serves as a valuable probe for analyzing the mechanisms of antigen processing and presentation by major histocompatibility complex (MHC) class I molecules. Utilizing this defined sequence, scientists can investigate the efficiency and specificity of peptide loading, presentation by antigen-presenting cells, and subsequent activation of cytotoxic T lymphocytes. These insights are crucial for understanding how tumor antigens are displayed to the immune system and for optimizing peptide-based vaccine strategies.

Immunogenicity assessment: In preclinical research, the melanoma-overexpressed antigen 1 (36-44) fragment is used to evaluate the immunogenic potential of tumor-associated peptides. When incorporated into immunization protocols or functional assays, it enables the assessment of T-cell activation, cytokine production, and cytolytic activity. Such studies provide foundational data for the rational design of peptide vaccines and immune monitoring tools in the context of melanoma and other malignancies expressing MELOE-1.

Peptide-MHC binding analysis: The defined sequence of this peptide makes it an excellent substrate for quantitative and qualitative studies of peptide-MHC interactions. By examining binding affinities and stability with various HLA alleles, researchers gain critical insights into the determinants of antigen presentation and the structural requirements for T-cell recognition. These findings inform the broader field of cancer immunology and support the development of more effective immunotherapeutic approaches.

Assay development: The availability of a well-characterized MELOE-1 (36-44) peptide enables the development and validation of immunological assays, such as ELISPOT, intracellular cytokine staining, and tetramer-based flow cytometry. These assays are essential for monitoring antigen-specific T-cell responses in experimental systems, facilitating the evaluation of immune interventions, and advancing translational research in tumor immunology. By serving as a reliable standard, the peptide supports reproducibility and comparability across diverse immunological investigations.

1. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

2. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

3. TMEM16F and dynamins control expansive plasma membrane reservoirs

4. The spatiotemporal control of signalling and trafficking of the GLP-1R

5. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes